Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1992-3-4
pubmed:abstractText
The neuroendocrine and clinical effects of transdermal 17 beta-estradiol (rated at 50 micrograms/day; TTS 50) were studied in 40 postmenopausal women; ten additional postmenopausal women did not receive any drugs. The changes in LH and rectal temperature induced by the infusion of the opioid antagonist naloxone (10 mg i.v. bolus plus 10 mg/h for 4 h) were used to evaluate the central activity of endogenous opioid peptides. TTS 50 increased opioid activity, as evidenced by the restoration of the LH response (P less than 0.01) and the enhancement of the hypothermic effect (P less than 0.05) of naloxone. A greater reduction in hot flushes was observed in TTS 50-treated subjects than in untreated women, with the maximal effect of TTS 50 achieved after 3 months of therapy. TTS 50 did not modify the concentrations of circulating lipids, glucose or liver enzymes but reduced the biochemical parameters indicative of bone reabsorption. Bone density of the distal radius significantly increased during TTS 50 (P less than 0.02), reaching its maximum value after 6 months of therapy. Thereafter bone density declined, but more slowly than in untreated women. Our data suggest that TTS 50 has marked neuroendocrine effects, that it diminishes the incidence of hot flushes and reduces bone demineralization. By contrast, it has a very little, if any, metabolic impact on the liver or on glucose and lipid metabolism.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0378-5122
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
283-96
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:1775082-Administration, Cutaneous, pubmed-meshheading:1775082-Adult, pubmed-meshheading:1775082-Alkaline Phosphatase, pubmed-meshheading:1775082-Body Temperature, pubmed-meshheading:1775082-Bone Density, pubmed-meshheading:1775082-Calcium, pubmed-meshheading:1775082-Estradiol, pubmed-meshheading:1775082-Estrogen Replacement Therapy, pubmed-meshheading:1775082-Estrone, pubmed-meshheading:1775082-Female, pubmed-meshheading:1775082-Flushing, pubmed-meshheading:1775082-Follicle Stimulating Hormone, pubmed-meshheading:1775082-Humans, pubmed-meshheading:1775082-Lipids, pubmed-meshheading:1775082-Luteinizing Hormone, pubmed-meshheading:1775082-Menopause, pubmed-meshheading:1775082-Middle Aged, pubmed-meshheading:1775082-Naloxone, pubmed-meshheading:1775082-Progesterone, pubmed-meshheading:1775082-Prolactin
pubmed:year
1991
pubmed:articleTitle
Neuroendocrine and clinical effects of transdermal 17 beta-estradiol in postmenopausal women.
pubmed:affiliation
Department of Obstetrics and Gynecology, University of Pisa, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial